Characterization of T cell, B cell and Natural Killer Cell Subsets in COVID-19 Patients

Abstract

Data from the Coronavirus-19 disease (COVID-19) pandemic suggests asthma is not a risk factor for severe disease in adults; it is unclear if this applies to pediatric patients. This study was undertaken to determine if pediatric patients with asthma or atopic disease had altered risk for severe disease when hospitalized with COVID-19. METHODS: A retrospective chart review was performed of SARS-CoV-2 positive patients admitted to Nationwide Children's Hospital from March 1 to July 31. Charts were evaluated for history of asthma or atopic disease (including asthma) and surrogate markers of COVID-19 severity, including ICU admission, supplemental oxygen requirement, and intubation. RESULTS: 49 patients were identified as positive for SARS-CoV-2, 22 of whom were admitted for COVID-19 related symptoms. Of the admitted patients, six patients (12%) had asthma and 18 (37%) atopic disease (including those with asthma). ICU admission rate for asthma versus nonasthma was 17% versus 12% (p50.78) and for atopic versus non-atopic was 17% versus 6.4% (p50.32), while supplemental oxygen rates were 17% versus 16% asthma versus non-asthma (p50.98) and 22% versus 13% atopic versus non-atopic (p50.43). Only two patients required intubation and both had atopic dermatitis. Two patients had Multisystem Inflammatory Syndrome in Children -one with allergic rhinitis and atopic dermatitis, the other without any atopic disease. CONCLUSIONS: Markers of COVID-19 disease severity do not differ based on asthma or atopic status in pediatric patients. In children, like adults, the presence of asthma or atopy does not appear to alter the risk of severe COVID-19.248 COVID-19 pandemia: Atopy and prospective analysis of the clinical evolution of patients infected with the SARS-CoV-2 virus

Activation of Herpes Viral Infection as a Manifestation of Post-Covid Syndrome

“…При вирусных инфекциях уровни миелоидных супрессорных клеток значительно повышены, и они могут подавлять активность Т-клеток [29]. Единого мнения по поводу того, имеет ли это расширение патогенные или защитные эффекты у пациентов с COVID-19, нет [11,58].…”